Method of preparing an antigen-containing formulation

Details Method of preparing an antigen-containing formulation Method of preparing an antigen-containing formulation

2002-08-02

2010-10-19

Szperka, Michael (Department: 1644)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C424S283100, C424S184100

Reexamination Certificate

active

07815920

ABSTRACT:
An antigen-containing formulation is provided, comprising: (a) an antigen; (b) a TH1-inducing adjuvant; and (c) a sparingly soluble amino acid or a derivative thereof. The adjuvant may be, for example, monophosphoryl lipid A, 3′-de-O-acetylated monophosphoryl lipid A, derivatives thereof, or any other adjuvant that enhances an individual's TH1 response to the antigen. Suitable amino acids include tyrosine, tryptophan, derivatives thereof, and the like. Methods for using the formulation are also provided; in a particularly preferred embodiment, the formulation is used as a vaccine.

REFERENCES:
patent: 3541201 (1970-11-01), Brown
patent: 3792159 (1974-02-01), Green et al.
patent: 4070455 (1978-01-01), Green et al.
patent: 4258029 (1981-03-01), Moloney et al.
patent: 4912094 (1990-03-01), Myers et al.
patent: 4956489 (1990-09-01), Auriol et al.
patent: 4987237 (1991-01-01), Myers et al.
patent: 5244663 (1993-09-01), Bruttmann et al.
patent: 5750110 (1998-05-01), Prieels et al.
patent: 5762943 (1998-06-01), Dolovich et al.
patent: 5776468 (1998-07-01), Hauser et al.
patent: 5795862 (1998-08-01), Frank et al.
patent: 5973128 (1999-10-01), Lingwood et al.
patent: 5997873 (1999-12-01), Srivastava
patent: 6146632 (2000-11-01), Momin et al.
patent: 2003/0165512 (2003-09-01), Wheeler et al.
patent: 2005/0123570 (2005-06-01), Ulrich et al.
patent: 0239400 (1994-08-01), None
patent: 0640347 (1995-03-01), None
patent: 0182442 (1996-04-01), None
patent: 0988862 (2001-06-01), None
patent: 1031347 (2002-04-01), None
patent: 1128637 (1968-09-01), None
patent: 1377074 (1974-12-01), None
patent: 1492973 (1977-11-01), None
patent: 2220211 (1990-01-01), None
patent: WO 92/16556 (1992-10-01), None
patent: WO 94/27636 (1994-12-01), None
patent: WO 95/05850 (1995-03-01), None
patent: WO 95/17209 (1995-06-01), None
patent: WO 96/25664 (1996-08-01), None
patent: WO 96/34626 (1996-11-01), None
patent: WO 98/43670 (1998-10-01), None
patent: WO 98/44947 (1998-10-01), None
patent: WO 98/58956 (1998-12-01), None
patent: WO 99/10375 (1999-03-01), None
patent: WO 99/16884 (1999-04-01), None
patent: WO 99/24577 (1999-05-01), None
patent: WO 99/64067 (1999-12-01), None
patent: WO 99/66043 (1999-12-01), None
patent: 00/29582 (2000-05-01), None
patent: 00/50078 (2000-08-01), None
patent: 00/62801 (2000-10-01), None
patent: 00/65058 (2000-11-01), None
patent: 00/72876 (2000-12-01), None
patent: 00/78353 (2000-12-01), None
patent: 01/29214 (2001-04-01), None
patent: 01/51082 (2001-07-01), None
Stearyl Tyrosine information page.
Cleland et al. Critical Reviews in Therp. Drug Carrier Systemes, 10(4):307-377, 1993.
Holen et al. “Specific T cell lines for ovalbumin, ovomucoid, lysozyme and two OA synthetic epitopes, generated from egg allergic patients' PBMC,”Clin. Exp. Allerg. (1996) 26:1080-1088, abstract.
Hoyne et al., “Peptide-mediated regulation of the allergic immune response,”Immunol. Cell Biol. (1996) 74:180-186.
Ngo et al. (1994),The Protein Folding Problem and Tertiary Structure Prediction, Mertz, Jr. et al. Eds., Birkhauser Boston, pp. 491-495.
Schneerson, et al., “Evaluation of monophosphoryl lipid A MPL as an adjuvant enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL,” J. Immunol. (1991) 147:2136-2140.
Ulrich and Myers, “Monophosphoryl Lipid A as an Adjuvant. Past Experiences and New Directions,” Vaccine Design: The Subunit and Adjuvant Approach (Powell & Newman, eds., Plenum Press, N.Y. 1995).
Marsh,Preparation and Properties of “Allergoids” Derived from Native Pollen by Mild Formalin Treatment, Int. Arch. Allergy 41:199-215 (1971).
Allergy Therapeutics Pollinex Quattro® Brochure (1999).
Office Action for U.S. Appl. No. 11/040,952, dated Oct. 30, 2008, Double-Patenting Rejection.
Office Action for U.S. Appl. No. 11/040,952, dated Jul. 8, 2009, Double-Patenting Rejection.
Cox et al. (1997), “Adjuvants—A Classification and Review of Their Modes of Action,”Vaccine15(3):248-256.
Nixon-George et al. (1990), “The Adjuvant Effect of Stearyl Tyrosine on a Recombinant Subunit Hepatitis B Surface Antigen,”The Journal of Immunology144(12):4798-4802.
Penney et al. (1993), “Further Studies on the Adjuvanticity of Stearyl Tyrosine and Ester Analogues,”Vaccine11:1129-1134.
Sasaki et al. (1998), “Comparison of Intranasal and Intramuscular Immunization Against Human Immunodeficiency Virus Type 1 with a DNA-Monophosphoryl Lipid A Adjuvant Vaccine,”Infection and Immunity66(2):823-826.
Scalzo et al. (1995), “Induction of Protective Cytotoxic T Cells to Murine Cytomegalovirus by Using a Nonapeptide and a Human-Compatible Adjuvant,”Journal of Virology69(2):1306-1309.
Wheeler et al. (1982), “L-Tyrosine as an Immunological Adjuvant,”Int. Archs Allergy appl. Immun. 69:113-119.
Ribi Adjuvant Fact Sheet (2003).
Akahira-Azuma et al., Early Delayed-Type Hypersensitivity Eosinophil Infiltrates Depend on T Helper 2 Cytokines and Interferon-Gamma via CXCR3 Chemokines, Immunology 111:306-317 (2004).
Chauncey et al., Enzymes of Human Saliva, The Determination, Distribution, and Origin of Whole Saliva Enzymes, J. Dental Res. 33(3):321-334 (1954).
Chauncey, Salivary Enzymes, J. Am. Dental Assoc. 63:42-50 (1961).
Dalton et al., The Solubilities of Certain Amino Acids in Water, the Densities of Their Solutions At Twenty-five Degrees, and The Calculated Heats of Solution and Partial Molal Volumes, J. Biol. Chem. 103(2):549-576 (1933).
Dearman et al., Divergent Antibody Isotype Responses Induced in Mice by Systemic Exposure to Proteins: a Comparison of Ovalbumin with Bovine Albumin, Food and Chemical Toxicology 38:351-360 (2000).
Dehlink et al., Absence of Systemic Immunologic Changes During Dose Build-up Phase and Early Maintenance Period in Effective Specific Sublingual Immunotherapy in Children, Clinical and Experimental Allergy 36:32-39 (2006).
Drachenberg et al., A Well-Tolerated Grass Pollen-Specific Allergy Vaccine Containing a Novel Adjuvant, Monophosphoryl Lipid A, Reduces Allergic Symptoms after only Four Preseasonal Injections, Allergy 498-505 (2001).
Drachenberg et al., Short-Term Immunotherapy with Tree Pollen Allergoids and the Adjuvant Monophosphoryl A—Results from a Multi-Centre, Placebo-Controlled Randomised, Double-Blind Study, Allergologie 25(9):466-474 (2002).
Drachenberg et al., Short-Term Immunotherapy Using an Allergy Vaccine Adjuvanted with Monophosphoryl Lipid A: A Post-Marketing Surveillance Study, Int. Rev. Allergol. Clin. Immunol. 8(4):219-223 (2002).
Drachenberg et al., Efficacy and Tolerability of Short-Term Specific Immunotherapy with Pollen Allergoids Adjuvanted by Monophosphoryl Lipid A (MPL) for Children and Adolescents, Allergol ET Immunopathol 31 (5):270-277 (2003).
Dunn et al., The Solubility of the Amino Acids in Water, J. Biol. Chem. 103(2):579-595 (1933).
Garren et al., Buccal Drug Absorption. I. Comparative Levels of Esterase and Peptidase Activities in Rat and Hamster Buccal and Intestinal Homogenates, Int'l J. Pharmaceutics 48:189-194 (1988).
Gonzalez-Hernandez et al., Peripheral Blood CD161+T Cells from Asthmatic Patients are Activated During Asthma Attack and Predominantly Produce IFN-Gamma Scand, J. Immunol. 65:368-375 (2007).
Hertl et al., Immunologic Mechanisms in Hypersensitivity Reactions to Metal Ions: an Overview, Allergy 55:108-115 (2000).
Jackson et al., Reduction of Human Anti-Tetanus Toxoid Antibody in hu-PBL-SCID mice by Immunodominant Peptides of Tetanus Toxoid, Clin Exp Immunol 137:245-252 (2004).
Johansen et al., Immunogenicity and Protective Efficacy of a Formalin-Inactivated Rotavirus Vaccine Combined with Lipid Adjuvants, Vaccine 21:368-375 (2003).
Lindquist et al., Esterases in Human Saliva, Enzyme, 20:277-291 (1975).
Lindquist et al., Origin of Esterases in Human Whole Saliva, Enzyme, 22:166-175 (1977).
Mamessier et al., Cytokines in Atopic Diseases: Revisiting the Th2 Dogma, Eur. J. Dermatol. 16(2):103-113 (2006).
Marsh et al.,

Affiliated with

Also associated with

Rating

Method of preparing an antigen-containing formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of preparing an antigen-containing formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preparing an antigen-containing formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4173975